Kymera Therapeutics Inc (KYMR)
37.90
-0.71
(-1.84%)
USD |
NASDAQ |
May 10, 16:00
37.85
-0.05
(-0.13%)
Pre-Market: 20:00
Kymera Therapeutics Profit Margin (Quarterly): -472.0% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -472.0% |
| December 31, 2023 | -30.01% |
| September 30, 2023 | -1.12K% |
| June 30, 2023 | -235.0% |
| March 31, 2023 | -432.4% |
| December 31, 2022 | -216.0% |
| September 30, 2022 | -450.2% |
| June 30, 2022 | -349.6% |
| March 31, 2022 | -381.3% |
| December 31, 2021 | -221.9% |
| Date | Value |
|---|---|
| September 30, 2021 | -140.5% |
| June 30, 2021 | -133.2% |
| March 31, 2021 | -69.91% |
| December 31, 2020 | -99.22% |
| September 30, 2020 | -54.95% |
| June 30, 2020 | -425.5% |
| March 31, 2020 | -318.9% |
| December 31, 2019 | -628.1% |
| September 30, 2019 | -1.20K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.20K%
Minimum
Sep 2019
-30.01%
Maximum
Dec 2023
-367.3%
Average
-318.9%
Median
Mar 2020
Profit Margin (Quarterly) Benchmarks
| Immunic Inc | -- |
| Insmed Inc | -208.1% |
| SELLAS Life Sciences Group Inc | -- |
| Iovance Biotherapeutics Inc | -24.15K% |
| Intellia Therapeutics Inc | -371.3% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -32.22% |
| Return on Assets | -24.21% |
| Return on Invested Capital | -32.22% |
| Operating Margin (Quarterly) | -514.3% |
| Return on Net Operating Assets | -161.0% |